News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
NOXXON Pharma AG Announces Appointment of Lawrence E. Posner to Its Board of Directors
July 8, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
BERLIN--(BUSINESS WIRE)--NOXXON Pharma AG (NOXXON), developer of mirror image oligonucleotide therapeutics termed Spiegelmers®, announced today the appointment of Lawrence E. Posner, MD, to its Board of Directors.
Twitter
LinkedIn
Facebook
Email
Print
People
Europe
MORE ON THIS TOPIC
Manufacturing
Samsung Biologics inks $262M manufacturing deal with European pharma company
September 11, 2026
·
2 min read
·
Nick Paul Taylor
Venture capital
Frazier adds $1.1B+ to small and mid-sized biotech fund
September 11, 2026
·
2 min read
·
Tristan Manalac
Business
Takeda’s long-term R&D head announces exit after major pipeline reorganization
September 10, 2026
·
2 min read
·
Gabrielle Masson
Drug pricing
Drugmakers cherry pick launch regions as MFN creates ‘policy environment like an earthquake’
September 10, 2026
·
4 min read
·
Annalee Armstrong
